DSpace

DSpace at RU >

Browsing by Author Hagen, T.L.M. ten

Jump to a point in the index:
Or type in a year:
Sort by: In order: Results/Page Authors/Record:
Showing results 1 to 11 of 11
Full TextIssue DateTitleAuthor(s)
2011Crossing barriers: the new dimension of 2D cell migration assays.Horssen, R. van; Hagen, T.L.M. ten
2010Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.Bouwhuis, M.G.; Suciu, S.; Testori, A.; Kruit, W.H.; Sales, F., et al
2009Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.Bouwhuis, M.G.; Suciu, S.; Collette, S.; Aamdal, S.; Kruit, W.H., et al
2009Modulation of cell motility by spatial repositioning of enzymatic ATP/ADP exchange capacity.Horssen, R. van; Janssen, E.E.W.; Peters, W.J.M; Pasch, L. van de; Lindert, M.M., et al
2008Cytokine detection in cells and tissues: complicated lessons from proEMAP/p43 and EMAP-II.Horssen, R. van; Rens, J.A.; Hagen, T.L.M. ten
2006Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.Horssen, R. van; Eggermont, A.M.M.; Hagen, T.L.M. ten
2006Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.Horssen, R. van; Rens, J.A.; Brunstein, F.; Guns, V.; Gils, M. van, et al
2006TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.Horssen, R. van; Hagen, T.L.M. ten; Eggermont, A.M.M.
2006EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.Horssen, R. van; Rens, J.A.; Schipper, D.; Eggermont, A.M.M.; Hagen, T.L.M. ten
2006Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay.Horssen, R. van; Galjart, N.; Rens, J.A.; Eggermont, A.M.M.; Hagen, T.L.M. ten
2004Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.Brouckaert, P.; Takahashi, N.; Tiel, S.T.; Hostens, J.; Eggermont, A.M.M., et al
Showing results 1 to 11 of 11

 

  DSpace Software Copyright © 2002-2011  Duraspace - Feedback